Let me tell you something horrible today: please see the "progress bar" of 2018 which is about to reach 1/3. Does everyone feel the same way as me that they have just "recovered" from the Spring Festival? Joking apart, many big things have happened during the past 1/3 of 2018, and the listing of the CRO giant WuXi AppTec could be definitely counted one thereof. Today, I want to analyze the pharmaceutical enterprises that have successfully been listed and those that failed in 2018.

Pharmaceutical enterprises that have applied for listing in China in 2018
|
Application date |
Company name |
Current state |
Date of submission |
Exchange to be listed on |
|
January 16, 2018 |
Gan & Lee Pharmaceuticals Co., Ltd. |
Submission passed |
April 3, 2018 |
Shanghai Stock Exchange |
|
February 6, 2018 |
Beijing Konruns Pharmaceutical Co., Ltd. |
Voting deferred |
|
Shanghai Stock Exchange |
|
February 6, 2018 |
WuXi AppTec Co., Ltd. |
Submission passed |
March 27, 2018 |
Shanghai Stock Exchange |
|
March 19, 2018 |
Hainan Zhonghe Pharmaceutical Co., Ltd. |
No submission |
|
Shanghai Stock Exchange |
(Source: eastmoney.com, excluding medical device companies, by April 16, 2018)
There have been 4 pharmaceutical enterprises that have applied for listing in China so far, wherein, Gan & Lee Pharmaceuticals and WuXi AppTec have succeeded in the submission (of listing application to the Issuance Review Committee of China Securities Regulatory Commission), while the future of Beijing Konruns Pharmaceutical and Hainan Zhonghe Pharmaceutical is unclear.
Gan & Lee Pharmaceuticals finally succeeded in the second submission
According to the prospectus of Gan & Lee Pharmaceuticals, the company plans to publicly issue not more than 40.20 million shares on Shanghai Stock Exchange and plans to raise fund of about RMB 2.519 billion, wherein, RMB 558 million will be used to supplement the working capital, and the rest will be invested in marketing network construction project, registration and marketing of the recombinant insulin glargine product in the U.S., insulin industrialization, and other four projects.
Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical enterprise that focuses on the biosynthetic insulin analogs, with the growth of the main business income mostly from insulin preparations, with single product structure. According to data, the sales revenue of insulin preparations separately accounted for 85.9%, 95.02%, 95.72% and 96.76% of the main business income of the com...










(All Rights Reserved)